cholangiocarcinoma

(redirected from Bile duct tumor)
Also found in: Dictionary.

cholangiocarcinoma

 [ko-lan″je-o-kahr″sĭ-no´mah]
1. an adenocarcinoma arising from the epithelium of the intrahepatic bile ducts, composed of eosinophilic cuboidal or columnar epithelial cells, with abundant fibrous stroma; mucus may be secreted but not bile.

chol·an·gi·o·car·ci·no·ma

(kō-lan'jē-ō-kar'si-nō'mă),
An adenocarcinoma, primarily in intrahepatic bile ducts, composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant fibrous stroma; cirrhosis is usually absent.

cholangiocarcinoma

/cho·lan·gi·o·car·ci·no·ma/ (ko-lan″je-o-kahr″sĭ-no´mah)
1. an adenocarcinoma arising from the epithelium of the intrahepatic bile ducts and composed of epithelial cells in tubules or acini with fibrous stroma.

cholangiocarcinoma

[kōlan′jē·ōkär′sinō′mə]
a cancer of the biliary epithelium. Risk factors include ulcerative colitis and infestation of liver flukes. Diagnosis is based on histological evaluation, and the prognosis is poor.

cholangiocarcinoma

A rare (5/105/year) cancer of intrahepatic bile ducts, seen > age 60.
 
Aetiology
Anabolic steroids, liver flukes (Clonorchis sinensis), ulcerative colitis, cholecystitis, cholelithiasis, primary sclerosing cholangitis, malformations, cirrhosis.

Clinical findings
Obstruction, jaundice, abdominal pain, weight loss.

Location
Hilar, 50–60%; intrahepatic, 10%; extrahepatic 20–30%.

Prognosis
53% 1-year survival; 4% 5-year survival.

cholangiocarcinoma

Bile duct cancer, cancer of bile ducts A rare–5/100,000/yr cancer of intrahepatic bile ducts seen > age 60 Etiology Anabolic steroids, Thorotrast,.Clonorchis sinensis, possibly ulcerative cholitis, cholecystitis; not associated with alcohol abuse Clinical Jaundice—71%, abdominal pain-49%, weight loss—44% Prognosis 53% 1-yr survival, 9% 3-yr, 4% 5-yr. Cf Hepatocellular carcinoma.

chol·an·gi·o·car·ci·no·ma

(kō-lan'jē-ō-kahr-si-nō'mă)
An adenocarcinoma, primarily in intrahepatic bile ducts, composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant fibrous stroma.

cholangiocarcinoma

Cancer of the bile ducts.

cholangiocarcinoma

see cholangiocellular carcinoma.
References in periodicals archive ?
Ampullary malignancies are less common than bile duct tumors but represent an important opportunity for an early diagnosis and aggressive therapy for a biliary malignancy.
The use of radiotherapy in conjunction with endoscopic stenting has failed to reduce the need for restenting in patients with bile duct tumors.
Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase III clinical trial in bile duct tumors is ongoing and which has been exclusively licensed to Helsinn Healthcare SA with rights to reacquire commercial rights for North America; XL784, initially an anticancer compound, which completed a Phase I clinical trial and is being advanced as a treatment for renal disease; XL647, XL999, XL880 and XL820, anticancer compounds currently in Phase I clinical trials; XL844 and XL184, anticancer compounds for which INDs have been filed; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders.
Bile duct tumors, bladder cancer, brain tumors, breast cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, gastric cancer, glioblastoma, head & neck cancer, hepatocellular carcinoma, leukemia's, lung cancer, lymphoma's, melanoma, mesothelioma, multiple myeloma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, sarcoma, thyroid cancer
The Phase 3 trial includes approximately 60 centers in the United States, Canada and Europe and is designed to enroll up to 600 patients with inoperable bile duct tumors.